Literature DB >> 18586871

Hypermucoviscosity as a virulence factor in experimental Klebsiella pneumoniae endophthalmitis.

Brandt J Wiskur1, Jonathan J Hunt, Michelle C Callegan.   

Abstract

PURPOSE: Klebsiella pneumoniae is a common cause of endogenous bacterial endophthalmitis, a disease that frequently results in a poor visual outcome. Hypermucoviscosity has been identified as a virulence factor among clinical bacteremia isolates of K. pneumoniae. In this study, an experimental murine model of K. pneumoniae endophthalmitis was established, and the role of hypermucoviscosity in its pathogenesis was analyzed.
METHODS: C57BL/6J mice were intravitreously injected with 100 CFU of hypermucoviscous (HMV+) or nonhypermucoviscous (HMV-) K. pneumoniae. Intraocular bacterial growth, retinal function, gross pathology, and inflammatory responses were monitored every 3 hours until the eyes lost significant (>90%) retinal function, or the infection appeared to clear.
RESULTS: The HMV+ strain grew logarithmically in eyes until approximately 15 hours postinfection (PI), reaching a stationary phase of growth at approximately 8.0 log(10) CFU/eye. The HMV- strain grew logarithmically to approximately 7.6 log(10) by 18 hours, but bacterial count declined to approximately 6.4 log(10) CFU/eye by 21 hours PI. Eyes infected with the HMV+ strain retained approximately 35% a-wave and <10% b-wave function by 18 hours PI. These eyes also had a cumulative clinical score of 14+ by 18 hours and underwent phthisis between 21 and 24 hours. Eyes infected with the HMV- strain had a cumulative clinical score of <6 and retained >60% a-wave and >50% b-wave function throughout 21 hours. Five of 7 eyes had <100 CFU HMV- K. pneumoniae at 27 hours PI.
CONCLUSIONS: The findings demonstrate the site-threatening consequences of K. pneumoniae endophthalmitis and the importance of the hypermucoviscosity phenotype in the pathogenesis of experimental K. pneumoniae endophthalmitis.

Entities:  

Mesh:

Year:  2008        PMID: 18586871      PMCID: PMC2576484          DOI: 10.1167/iovs.08-2276

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  42 in total

1.  Nosocomial infection with cephalosporin-resistant Klebsiella pneumoniae is not associated with increased mortality.

Authors:  Cristiana C Gomes; Evangelina Vormittag; Cleide R Santos; Anna S Levin
Journal:  Infect Control Hosp Epidemiol       Date:  2006-07-31       Impact factor: 3.254

2.  The incidence of endophthalmitis after cataract surgery among the U.S. Medicare population increased between 1994 and 2001.

Authors:  Emily S West; Ashley Behrens; Peter J McDonnell; James M Tielsch; Oliver D Schein
Journal:  Ophthalmology       Date:  2005-08       Impact factor: 12.079

3.  Impaired phagocytosis of capsular serotypes K1 or K2 Klebsiella pneumoniae in type 2 diabetes mellitus patients with poor glycemic control.

Authors:  Jung-Chung Lin; L K Siu; Chang-Phone Fung; Hsiao-Hui Tsou; Jaang-Jiun Wang; Chiung-Tong Chen; Shu-Chuan Wang; Feng-Yee Chang
Journal:  J Clin Endocrinol Metab       Date:  2006-05-23       Impact factor: 5.958

4.  magA is not a specific virulence gene for Klebsiella pneumoniae strains causing liver abscess but is part of the capsular polysaccharide gene cluster of K. pneumoniae serotype K1.

Authors:  Kuo-Ming Yeh; Feng-Yee Chang; Chang-Phone Fung; Jung-Chung Lin; L K Siu
Journal:  J Med Microbiol       Date:  2006-06       Impact factor: 2.472

5.  Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella pneumoniae.

Authors:  Deverick J Anderson; John J Engemann; Lizzie J Harrell; Yehuda Carmeli; L Barth Reller; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

6.  Phage associated bacteriocins reveal a novel mechanism for bacteriocin diversification in Klebsiella.

Authors:  Milind Chavan; Hamid Rafi; John Wertz; Carla Goldstone; Margaret A Riley
Journal:  J Mol Evol       Date:  2005-04       Impact factor: 2.395

7.  Clinical implications of hypermucoviscosity phenotype in Klebsiella pneumoniae isolates: association with invasive syndrome in patients with community-acquired bacteraemia.

Authors:  H-C Lee; Y-C Chuang; W-L Yu; N-Y Lee; C-M Chang; N-Y Ko; L-R Wang; W-C Ko
Journal:  J Intern Med       Date:  2006-06       Impact factor: 8.989

8.  Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.

Authors:  Ken B Waites; Lynn B Duffy; Michael J Dowzicky
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

9.  Association between rmpA and magA genes and clinical syndromes caused by Klebsiella pneumoniae in Taiwan.

Authors:  Wen-Liang Yu; Wen-Chien Ko; Kuo-Chen Cheng; Hsin-Chun Lee; Der-Shin Ke; Ching-Chien Lee; Chang-Phone Fung; Yin-Ching Chuang
Journal:  Clin Infect Dis       Date:  2006-04-11       Impact factor: 9.079

10.  A novel virulence gene in Klebsiella pneumoniae strains causing primary liver abscess and septic metastatic complications.

Authors:  Chi-Tai Fang; Yi-Ping Chuang; Chia-Tung Shun; Shan-Chwen Chang; Jin-Town Wang
Journal:  J Exp Med       Date:  2004-03-01       Impact factor: 14.307

View more
  27 in total

1.  Successful treatment of endogenous Klebsiella pneumoniae endophthalmitis: a case report.

Authors:  Kotaro Ishii; Takahiro Hiraoka; Yuichi Kaji; Norishige Sakata; Yuta Motoyama; Tetsuro Oshika
Journal:  Int Ophthalmol       Date:  2010-07-28       Impact factor: 2.031

Review 2.  Targets of immunomodulation in bacterial endophthalmitis.

Authors:  Frederick C Miller; Phillip S Coburn; Mursalin Md Huzzatul; Austin L LaGrow; Erin Livingston; Michelle C Callegan
Journal:  Prog Retin Eye Res       Date:  2019-05-28       Impact factor: 21.198

Review 3.  Modeling intraocular bacterial infections.

Authors:  Roger A Astley; Phillip S Coburn; Salai Madhumathi Parkunan; Michelle C Callegan
Journal:  Prog Retin Eye Res       Date:  2016-05-03       Impact factor: 21.198

4.  Contribution of mucoviscosity-associated gene A (magA) to virulence in experimental Klebsiella pneumoniae endophthalmitis.

Authors:  Jonathan J Hunt; Jin-Town Wang; Michelle C Callegan
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-29       Impact factor: 4.799

Review 5.  Bacterial and Fungal Endophthalmitis.

Authors:  Marlene L Durand
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

6.  Prevalence of and risk factors for endogenous endophthalmitis in patients with pyogenic liver abscesses.

Authors:  In Hyung Park; Chung Hwan Jun; Jin Woo Wi; Seon Young Park; Wan Sik Lee; Sook In Jung; Chang Hwan Park; Young Eun Joo; Hyun Soo Kim; Sung Kyu Choi; Jong Sun Rew
Journal:  Korean J Intern Med       Date:  2015-06-29       Impact factor: 2.884

7.  The diabetic ocular environment facilitates the development of endogenous bacterial endophthalmitis.

Authors:  Phillip S Coburn; Brandt J Wiskur; Elizabeth Christy; Michelle C Callegan
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-01       Impact factor: 4.799

8.  TLR4 contributes to the host response to Klebsiella intraocular infection.

Authors:  Jonathan J Hunt; Roger Astley; Nanette Wheatley; Jin-Town Wang; Michelle C Callegan
Journal:  Curr Eye Res       Date:  2014-03-03       Impact factor: 2.424

9.  Characterization of multidrug-resistant and virulent Klebsiella pneumoniae strains belonging to the high-risk clonal group 258 (CG258) isolated from inpatients in northeastern Brazil.

Authors:  Rafael Nakamura-Silva; Mariana Oliveira-Silva; João Pedro Rueda Furlan; Eliana Guedes Stehling; Carlos Eduardo Saraiva Miranda; André Pitondo-Silva
Journal:  Arch Microbiol       Date:  2021-06-10       Impact factor: 2.552

10.  Comparative study of genotype and virulence in CTX-M-producing and non-extended-spectrum-β-lactamase-producing Klebsiella pneumoniae isolates.

Authors:  Juyoun Shin; Kwan Soo Ko
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.